Can Nebius Monetize Its Bets on ClickHouse, Avride and Toloka?
Apart from booming core AI business, investors also need to look at the company's various stakes in some high-growth tech ventures that could emerge as powerful value drivers. ClickHouse stake is a standout. NBIS has a 28% stake in ClickHouse, valued at around $6 billion presently, which translates into a ready capital source if monetized. Other stakes include Toloka, a data partner for all stages of AI development, TripleTen, an edtech platform, and Avride, an autonomous vehicle platform.
NBIS holds a considerable majority economic interest stake in Toloka. This tech venture is now backed by Amazon's Jeff Bezos and Shopify's Mikhail Parakhin. This investment will enable Toloka to scale rapidly and enhance its focus as global demand for high-quality AI data continues to rise.
Avride struck partnerships with major players like Uber, Hyundai, GrubHub and Rakuten in the last reported quarter. Nebius also highlighted that discussions with potential third-party investors are underway, indicating another path to capital generation.
These various stakes give Nebius a unique edge among AI-infrastructure players. Nebius seems confident to effectively monetize these businesses and fuel its core business while minimizing dilution to existing shareholders and keeping debt in check. For investors, these hidden value drivers may represent the next leg of the company's valuation uplift.
How Are NBIS' Competitors Positione
d
?
CoreWeave CRWV is another AI-infrastructure company with hyper revenue growth of 420% in the first quarter of 2025. CRWV has been focused on own infrastructure buildout. The company acquired Weights & Biases as part of the strategy to expand its footprint in high-performance AI-cloud infrastructure.
CRWV also recently announced the acquistion of Core Scientifi c in an all-stock deal worth around $9 billion as it deepens the vertical integration strategy. By taking ownership of Core Scientific's 1.3 GW power infrastructure footprint, with an additional 1 GW expansion potential, it gains ample room to grow its AI infrastructure. With demand for AI compute soaring, this extra capacity provides a strong long-term advantage. The transaction, expected to close in the fourth quarter of 2025. Management has also inked a strategic partnership with OpenAI for about $11.9 billion.
Microsoft Corporation MSFT is a structurally dominant name in the tech space. With its Azure cloud platform, MSFT leads the AI-infrastructure space. The tech giant invests in innovative early-stage tech companies through its M12 venture fund. MSFT boasts stakes in various companies, with the crown jewel being OpenAI. MSFT has invested $13 billion in OpenAI and has rights to OpenAI IP (includes both model and infrastructure) for use within its products like Copilot, Azure and Bing.
Moreover, Azure platform is the exclusive cloud provider for OpenAI. Through the Azure OpenAI Service agreement, developers can have direct access to leading OpenAI models supported by Azure and AI infrastructure and tools.
NBIS Price Performance, Valuation and Estimates
Shares of Nebius have gained 87.5% year to date compared with the Internet – Software and Services industry's growth of 23.8%.
Image Source: Zacks Investment Research
In terms of price/book, NBIS' shares are trading at 3.87X, down from the Internet Software Services industry's ratio of 4.1X.
The Zacks Consensus Estimate for NBIS' earnings for 2025 has been unchanged over the past 30 days.
NBIS currently carries a Zacks Rank #4 (Sell).
You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
7 Best Stocks for the Next 30 Days
Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops."
Since 1988, the full list has beaten the market more than 2X over with an average gain of +23.5% per year. So be sure to give these hand picked 7 your immediate attention.
See them now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Microsoft Corporation (MSFT): Free Stock Analysis Report
Nebius Group N.V. (NBIS): Free Stock Analysis Report
CoreWeave Inc. (CRWV): Free Stock Analysis Report
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
20 minutes ago
- Globe and Mail
Imagen Network (IMAGE) Expands Web3 Utility with Binance Wallet Compatibility
Enhanced wallet connectivity improves access to AI-powered social tools across multichain platforms. Singapore, Singapore--(Newsfile Corp. - July 23, 2025) - Imagen Network, the decentralized AI social platform, now supports compatibility with Binance Wallet—enabling users to securely manage their $IMAGE tokens while interacting with decentralized features across Ethereum, BNB Chain, and Solana. To view an enhanced version of this graphic, please visit: This connectivity allows users to engage seamlessly with Imagen's AI content tools, community governance, and personalized social experiences directly through one of Web3's most trusted wallet solutions. By supporting wallet-based access, Imagen continues to prioritize multichain fluidity, user freedom, and secure self-custody. As part of its broader mission to power intelligent, creator-led ecosystems, Imagen Network leverages wallet interoperability to fuel seamless engagement with adaptive AI filters, modular social nodes, and tokenized participation tools. With this upgrade, Imagen reinforces its focus on accessible, cross-chain interaction and user-controlled digital identity within the expanding decentralized social landscape. About Imagen Network Imagen Network is a decentralized social platform that blends AI content generation with blockchain infrastructure to give users creative control and data ownership. Through tools like adaptive filters and tokenized engagement, Imagen fosters a new paradigm of secure, expressive, and community-driven networking. Media Contact Dorothy Marley KaJ Labs +1 707-622-6168 media@ Social Media Twitter Instagram
Globe and Mail
20 minutes ago
- Globe and Mail
Cosmo Delivers Strong Performance in H1 2025, Raises Full-Year EBITDA Guidance and Accelerates Recurring Revenue Growth Across AI and Dermatology
Ad hoc announcement pursuant to Art. 53 LR EBITDA guidance raised by €4.5M as Cosmo executes on its Vision 2030 strategy; H1 Recurring Revenues from GI Genius™ up 128%, Winlevi® up 23%; Investors Call today at 2 pm CET. Dublin, Ireland--(Newsfile Corp. - July 23, 2025) - Cosmo Pharmaceuticals N.V. (SIX: COPN), a global leader in AI-powered healthcare and specialty pharma, today reported strong half-year results for 2025, underscoring the Company's strategic execution, commercial momentum, and capital discipline across its key growth platforms. On the back of robust performance in H1 2025, Cosmo has raised its full-year EBITDA guidance by €4.5 million and reconfirmed its total revenue outlook for 2025, while confirming double-digit growth in recurring revenues – driven by its leading products and technologies in MedTech AI and Dermatology. H1 2025 Highlights Cosmo delivered strong financial and operational performance in the first half of 2025, with strong momentum in GI Genius™ and Winlevi®, continued cost discipline, and a strong balance sheet. Total Revenues: €51.7 million €41.9 million in recurring revenues €9.8 million in project-based revenues Growth Drivers: GI Genius™ recurring revenues: +128% YoY Winlevi® recurring revenues: +23% YoY Operating Expenses: €57.8 million Cost of Sales: €25.6 million (+10% YoY) R&D: €18.0 million (–6% YoY) SG&A: €14.3 million (–13% YoY) Cash, Equivalents, and Investments: €133.3 million as of June 30, 2025 Treasury Shares: 1.6 million shares held as of June 30, 2025 (~€97.7 million), an increase of 76.2K shares vs. December 31, 2024 H2 2025 Outlook Cosmo expects continued momentum in the second half of 2025, with: Recurring revenues: €43 – 48 million Continued triple digit growth from GI Genius®, double digit growth from Winlevi® and steady growth from Gastro and CDMO business. Increased R&D spending to advance Phase II programs for Bile Acid Diarrhoea and Distal Ulcerative Colitis. Continued SG&A discipline to drive margin expansion Strategic Context Cosmo operates at the intersection of high-growth global markets — AI in endoscopy, Dermatology, Gastrointestinal diseases, and advanced Drug Manufacturing. Each of these sectors is fuelled by large, persistent clinical unmet needs: In MedTech AI, Cosmo's GI Genius™ is redefining detection and diagnostic accuracy in real time. In Dermatology, Winlevi® is the first new acne mechanism of action in decades. In Gastroenterology, Cosmo's Phase II pipeline addresses conditions like Bile Acid Diarrhoea and distal ulcerative colitis. In CDMO, Cosmo supports global pharmaceutical partners with advanced formulation, regulatory, and sterile manufacturing expertise. What makes Cosmo unique is its ability to scale innovation across all four businesses — leveraging common R&D infrastructure, regulatory know-how, Artificial Intelligence, Digital capabilities, and manufacturing excellence. This integrated model is designed to unlock operational leverage, reduce time-to-market, and drive compounding long-term growth. Giovanni Di Napoli, Chief Executive Officer of Cosmo, commented: 'These results validate our strategy: we are scaling impact across high-need therapeutic areas with real momentum. What sets Cosmo apart is our ability to operate as one company with four powerful platforms: AI-powered MedTech, next-generation Dermatology, GI innovation, and high-value CDMO. These aren't isolated businesses, they reinforce each other, creating a scalable ecosystem with clinical, operational, and financial synergies. We're not just growing — we're compounding. And this is just the beginning of our 2030 vision.' Svetlana Sigalova, Chief Financial Officer of Cosmo, added: 'Our first-half results reflect strong execution, continued growth in recurring revenues, and prudent financial management. We remain disciplined in controlling costs and investing where it matters most. With a solid balance sheet and clear capital priorities, we're well positioned to support Cosmo's long-term growth and deliver on our 2030 ambition.' Analyst, media and investors call today at 2 pm CET Cosmo invites investors, financial analysts and business/life sciences journalists to a live webcast presentation which will follow today at 2:00 pm CET. To join via Web browser, click here To join via phone, please use one of the following dial-in numbers: Switzerland/Europe +41 (0) 58 310 50 00 United Kingdom +44 (0) 207 107 06 13 United States +1 (1) 631 570 56 13 Key figures EUR 1'000 H1 2025 H1 2024 (restated) Income statement Revenue 51,720 136,237 Recurring Revenues 41,925 42,379 Project Based Revenues 9,795 93,858 [1] Cost of sales (25,571) (23,150) Gross profit 26,149 113,087 Other income 4,701 1,122 R&D costs (17,997) (19,137) SG&A costs (14,264) (16,323) Net operating expenses (27,560) (34,338) Operating profit/(loss) (1,411) 78,749 Net financial income 741 1,794 Profit/(loss) before taxes (670) 80,543 Profit/(loss) after taxes for the period (2,030) 71,177 EBITDA 4,852 84,868 Statement of financial position As of 30 June 2025 As of 31 December 2024 Non-current assets 423,104 444,514 Cash and cash equivalents 50,749 44,296 Other current assets 136,477 157,962 Liabilities 143,354 141,681 Equity attributable to owners of the Company 460,239 498,330 Non-controlling interests 6,737 6,761 Equity ratio (%) 75.4% 77.0% Shares H1 2025 H1 2024 (restated) Weighted average number of shares 15,970,541 16,105,126 Earnings/(loss) per share (in EUR) (0.126) 4.423 The full Half-Year 2025 Report of Cosmo can be found for download as pdf-document on the Company's website via About Cosmo Cosmo is a life sciences company focused on MedTech AI, dermatology, gastrointestinal diseases, and contract development and manufacturing (CDMO). We design, develop, and manufacture advanced solutions that address critical medical needs and raise the standard of care. Our technologies are trusted by leading global pharmaceutical and MedTech companies and reach patients and healthcare providers around the world. Guided by our purpose - Building Health Confidence - our mission is to empower patients, healthcare professionals, and partners by innovating at the intersection of science and technology. Founded in 1997, Cosmo is headquartered in Dublin, Ireland, with offices in San Diego (USA), and in Lainate, Rome, and Catania (Italy). For more information, visit Financial calendar Attachments PDF - English
Winnipeg Free Press
an hour ago
- Winnipeg Free Press
These tips from experts can help your teenager navigate AI companions
As artificial intelligence technology becomes part of daily life, adolescents are turning to chatbots for advice, guidance and conversation. The appeal is clear: Chatbots are patient, never judgmental, supportive and always available. That worries experts who say the booming AI industry is largely unregulated and that many parents have no idea about how their kids are using AI tools or the extent of personal information they are sharing with chatbots. New research shows more than 70% of American teenagers have used AI companions and more than half converse with them regularly. The study by Common Sense Media focused on 'AI companions,' like Character. AI, Nomi and Replika, which it defines as 'digital friends or characters you can text or talk with whenever you want,' versus AI assistants or tools like ChatGPT, though it notes they can be used the same way. It's important that parents understand the technology. Experts suggest some things parents can do to help protect their kids: — Start a conversation, without judgment, says Michael Robb, head researcher at Common Sense Media. Approach your teen with curiosity and basic questions: 'Have you heard of AI companions?' 'Do you use apps that talk to you like a friend?' Listen and understand what appeals to your teen before being dismissive or saying you're worried about it. — Help teens recognize that AI companions are programmed to be agreeable and validating. Explain that's not how real relationships work and that real friends with their own points of view can help navigate difficult situations in ways that AI companions cannot. 'One of the things that's really concerning is not only what's happening on screen but how much time it's taking kids away from relationships in real life,' says Mitch Prinstein, chief of psychology at the American Psychological Association. 'We need to teach kids that this is a form of entertainment. It's not real, and it's really important they distinguish it from reality and should not have it replace relationships in your actual life.' The APA recently put out a health advisory on AI and adolescent well-being, and tips for parents. — Parents should watch for signs of unhealthy attachments. 'If your teen is preferring AI interactions over real relationships or spending hours talking to AI companions, or showing that they are becoming emotionally distressed when separated from them — those are patterns that suggest AI companions might be replacing rather than complementing human connection,' Robb says. — Parents can set rules about AI use, just like they do for screen time and social media. Have discussions about when and how AI tools can and cannot be used. Many AI companions are designed for adult use and can mimic romantic, intimate and role-playing scenarios. While AI companions may feel supportive, children should understand the tools are not equipped to handle a real crisis or provide genuine mental health support. If kids are struggling with depression, anxiety, loneliness, an eating disorder or other mental health challenges, they need human support — whether it is family, friends or a mental health professional. — Get informed. The more parents know about AI, the better. 'I don't think people quite get what AI can do, how many teens are using it and why it's starting to get a little scary,' says Prinstein, one of many experts calling for regulations to ensure safety guardrails for children. 'A lot of us throw our hands up and say, 'I don't know what this is!' This sounds crazy!' Unfortunately, that tells kids if you have a problem with this, don't come to me because I am going to diminish it and belittle it.' Older teenagers have advice, too, for parents and kids. Banning AI tools is not a solution because the technology is becoming ubiquitous, says Ganesh Nair, 18. 'Trying not to use AI is like trying to not use social media today. It is too ingrained in everything we do,' says Nair, who is trying to step back from using AI companions after seeing them affect real-life friendships in his high school. 'The best way you can try to regulate it is to embrace being challenged.' 'Anything that is difficult, AI can make easy. But that is a problem,' says Nair. 'Actively seek out challenges, whether academic or personal. If you fall for the idea that easier is better, then you are the most vulnerable to being absorbed into this newly artificial world.' ___ The Associated Press' education coverage receives financial support from multiple private foundations. AP is solely responsible for all content. Find AP's standards for working with philanthropies, a list of supporters and funded coverage areas at
